<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33689574</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
              <Day>31</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>11</EndPage>
          <MedlinePgn>1-11</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1891814</ELocationID>
        <Abstract>
          <AbstractText>Neoantigens play a crucial role in cancer immunotherapy. However, the effectiveness and safety of neoantigen-based immunotherapies in patients with colorectal cancer (CRC), particularly in the Chinese population, have not been well studied. This study explored the feasibility and effectiveness of neoantigens in the treatment of CRC. Whole-exome sequencing (WES) and transcriptome sequencing were used to identify somatic mutations, RNA expression, and human leukocyte antigen (HLA) alleles. Neoantigen candidates were predicted, and immunogenicity was assessed. The neoantigens TSHZ3-L523P, RARA-R83H, TP53-R248W, EYA2-V333I, and NRAS-G12D from Patient 4 (PW4); TASP1-P161L, RAP1GAP-S215R, MOSPD1-V63I, and NAV2-D1973N from Patient 10 (PW10); and HAVCR2-F39V, SEC11A-R11L, SMPDL3B-T452M, LRFN3-R118Q, and ULK1-S248L from Patient 11 (HLA-A0201<sup>+</sup>PW11) induced a heightened neoantigen-reactive T cell (NRT) response as compared with the controls in peripheral blood lymphocytes (PBLs) isolated from patients with CRC. In addition, we identified neoantigen-containing peptides SEC11A-R11L and ULK1-S248L from HLA-A0201<sup>+</sup>PW11, which more effectively elicited specific CTL responses than the corresponding native peptides in PBLs isolated from HLA-A0201<sup>+</sup>PW11 as well as in HLA-A2.1/K<sup>b</sup> transgenic mice. Importantly, adoptive transfer of NRTs induced by vaccination with two mutant peptides could effectively inhibit tumor growth in tumor-bearing mouse models. These data indicate that neoantigen-containing peptides with high immunogenicity represent promising candidates for peptide-mediated personalized therapy.<b>Abbreviations:</b> CRC: colorectal cancer; DCs: dendritic cells; ELISPOT: enzyme-linked immunosorbent spot; E:T: effector:target; HLA: human leukocyte antigen; MHC: major histocompatibility complex; Mut: mutant type; NGS: next-generation sequencing; NRTs: neoantigen-reactive T cells; PBMCs: peripheral blood mononuclear cells; STR: short tandem repeat; PBLs: peripheral blood lymphocytes; PBS: phosphate-buffered saline; PD-1: programmed cell death protein 1; TILs: tumor-infiltrating lymphocytes; RNA-seq: RNA sequencing; Tg: transgenic; TMGs: tandem minigenes; WES: whole-exome sequencing; WT: wild-type.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Yaojun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Surgery, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Leyi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yuesheng</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Hejie</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teng</LastName>
            <ForeName>Yangyang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Limiao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Zhanxiong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xue</LastName>
            <ForeName>Xiangyang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Wenzhou Medical University School of Basic Medicine, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>Xian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Surgery, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>Haiping</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Qingdao Central Hospital, The Second Affiliated Hospital, Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Su</LastName>
            <ForeName>Xiaoping</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Wenzhou Medical University School of Basic Medicine, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Weihong</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Biotherapy Center, Qingdao Central Hospital, The Second Affiliated Hospital, Qingdao University, Qingdao, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Zhenzhai</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018398">Homeodomain Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C580600">TSHZ3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.4.12</RegistryNumber>
          <NameOfSubstance UI="C508196">SMPDL3B protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.4.12</RegistryNumber>
          <NameOfSubstance UI="D013108">Sphingomyelin Phosphodiesterase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.-</RegistryNumber>
          <NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.89</RegistryNumber>
          <NameOfSubstance UI="C000591565">SEC11A protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018398" MajorTopicYN="N">Homeodomain Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013108" MajorTopicYN="N">Sphingomyelin Phosphodiesterase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Colorectal cancer</Keyword>
        <Keyword MajorTopicYN="Y">cancer vaccine</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">neoantigens</Keyword>
        <Keyword MajorTopicYN="Y">tumor</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>17</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33689574</ArticleId>
        <ArticleId IdType="pmc">PMC8920255</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2021.1891814</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Siegel RL, Miller KD, Jemal A.. 
Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21332</ArticleId>
            <ArticleId IdType="pubmed">26742998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32. doi:10.3322/caac.21338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21338</ArticleId>
            <ArticleId IdType="pubmed">26808342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biondi A, Vacante M, Ambrosino I, Cristaldi E, Pietrapertosa G, Basile F. Role of surgery for colorectal cancer in the elderly. World J Gastrointest Surg. 2016;8(9):606–13. doi:10.4240/wjgs.v8.i9.606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4240/wjgs.v8.i9.606</ArticleId>
            <ArticleId IdType="pmc">PMC5037333</ArticleId>
            <ArticleId IdType="pubmed">27721923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biondi A, Grosso G, Mistretta A, Marventano S, Toscano C, Drago F, Gangi S, Basile F. Laparoscopic vs. open approach for colorectal cancer: evolution over time of minimal invasive surgery. BMC Surg. 2013;13 Suppl 2(Suppl2):S12. doi:10.1186/1471-2482-13-s2-s12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2482-13-s2-s12</ArticleId>
            <ArticleId IdType="pmc">PMC3851244</ArticleId>
            <ArticleId IdType="pubmed">24267544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Loon K, Venook AP. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol. 2014;32(10):991–96. doi:10.1200/jco.2013.53.5195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2013.53.5195</ArticleId>
            <ArticleId IdType="pubmed">24516031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharif S, O’Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008;26(9):956–63. doi:10.1080/07357900802132550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07357900802132550</ArticleId>
            <ArticleId IdType="pmc">PMC2588473</ArticleId>
            <ArticleId IdType="pubmed">18798075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med. 2004;10(9):887–92. doi:10.1038/nm0904-887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0904-887</ArticleId>
            <ArticleId IdType="pubmed">15340404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy–revisited. Nat Rev Drug Discov. 2011;10(8):591–600. doi:10.1038/nrd3500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd3500</ArticleId>
            <ArticleId IdType="pubmed">21804596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.cd-14-0863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.cd-14-0863</ArticleId>
            <ArticleId IdType="pmc">PMC4293246</ArticleId>
            <ArticleId IdType="pubmed">25358689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–39. doi:10.1038/s41586-018-0792-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-018-0792-9</ArticleId>
            <ArticleId IdType="pmc">PMC6546179</ArticleId>
            <ArticleId IdType="pubmed">30568305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature22991</ArticleId>
            <ArticleId IdType="pmc">PMC5577644</ArticleId>
            <ArticleId IdType="pubmed">28678778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-Cell transfer therapy targeting mutant KRAS in Cancer. N Engl J Med. 2016;375(23):2255–62. doi:10.1056/NEJMoa1609279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609279</ArticleId>
            <ArticleId IdType="pmc">PMC5178827</ArticleId>
            <ArticleId IdType="pubmed">27959684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, Wan T, Zhou X, Wang B, Yang F, Li N, Chen G, Dai S, Liu S, Zhang M, et al. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Cancer Res. 2005;65(11):4947–54. doi:10.1158/0008-5472.can-04-3912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-04-3912</ArticleId>
            <ArticleId IdType="pubmed">15930317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, Fennell T, Giannoukos G, Fisher S, Russ C, et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol. 2009;27(2):182–89. doi:10.1038/nbt.1523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.1523</ArticleId>
            <ArticleId IdType="pmc">PMC2663421</ArticleId>
            <ArticleId IdType="pubmed">19182786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60. doi:10.1093/bioinformatics/btp324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btp324</ArticleId>
            <ArticleId IdType="pmc">PMC2705234</ArticleId>
            <ArticleId IdType="pubmed">19451168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh S, Chan CK. Analysis of RNA-seq data using tophat and cufflinks. Methods Mol Biol. 2016;1374:339–61. doi:10.1007/978-1-4939-3167-5_18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4939-3167-5_18</ArticleId>
            <ArticleId IdType="pubmed">26519415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen F, Zou Z, Du J, Su S, Shao J, Meng F, Yang J, Xu Q, Ding N, Yang Y, et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019;129(5):2056–70. doi:10.1172/jci99538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci99538</ArticleId>
            <ArticleId IdType="pmc">PMC6486339</ArticleId>
            <ArticleId IdType="pubmed">30835255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310–16. doi:10.1093/bioinformatics/btu548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btu548</ArticleId>
            <ArticleId IdType="pmc">PMC4441069</ArticleId>
            <ArticleId IdType="pubmed">25143287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weese D, Holtgrewe M, Reinert K, Razer S. 3: faster, fully sensitive read mapping. Bioinformatics. 2012;28(20):2592–99. doi:10.1093/bioinformatics/bts505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/bts505</ArticleId>
            <ArticleId IdType="pubmed">22923295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjerregaard AM, Nielsen M, Hadrup SR, Szallasi Z, Eklund AC. MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol Immunother. 2017;66(9):1123–30. doi:10.1007/s00262-017-2001-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-017-2001-3</ArticleId>
            <ArticleId IdType="pubmed">28429069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim B, Won D, Jang M, Kim H, Choi JR, Kim TI, Lee ST. Next-generation sequencing with comprehensive bioinformatics analysis facilitates somatic mosaic APC gene mutation detection in patients with familial adenomatous polyposis. BMC Med Genomics. 2019;12(1):103. doi:10.1186/s12920-019-0553-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12920-019-0553-0</ArticleId>
            <ArticleId IdType="pmc">PMC6610853</ArticleId>
            <ArticleId IdType="pubmed">31269945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–45. doi:10.1126/science.1251102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1251102</ArticleId>
            <ArticleId IdType="pmc">PMC6686185</ArticleId>
            <ArticleId IdType="pubmed">24812403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He JD, Luo HL, Li J, Feng WT, Chen LB. Influences of the interferon induced transmembrane protein 1 on the proliferation, invasion, and metastasis of the colorectal cancer SW480 cell lines. Chin Med J (Engl). 2012;125:517–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22490413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogura M, Kakuda T, Takarada T, Nakamichi N, Fukumori R, Kim YH, Hinoi E, Yoneda Y. Promotion of both proliferation and neuronal differentiation in pluripotent P19 cells with stable overexpression of the glutamine transporter slc38a1. PLoS One. 2012;7(10):e48270. doi:10.1371/journal.pone.0048270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0048270</ArticleId>
            <ArticleId IdType="pmc">PMC3480496</ArticleId>
            <ArticleId IdType="pubmed">23110224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol. 2001;166:5407–15. doi:10.4049/jimmunol.166.9.5407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.166.9.5407</ArticleId>
            <ArticleId IdType="pubmed">11313377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun W, Wei X, Niu A, Ma X, Li JJ, Gao D. Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides. Cancer Lett. 2015;369:112–23. doi:10.1016/j.canlet.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet</ArticleId>
            <ArticleId IdType="pubmed">26304717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage. 2012;20:256–60. doi:10.1016/j.joca.2012.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joca.2012.02.010</ArticleId>
            <ArticleId IdType="pubmed">22424462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slater AM, Cao LA. Protocol for housing mice in an enriched environment. J Visualized Exp. 2015;(100)e52874. doi:10.3791/52874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/52874</ArticleId>
            <ArticleId IdType="pmc">PMC4544994</ArticleId>
            <ArticleId IdType="pubmed">26131694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, Yi L, Ling M, Jiang J, Song L, Liu J, Cao X. HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer. Cell Mol Immunol. 2018;15(2):135–45. doi:10.1038/cmi.2016.33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cmi.2016.33</ArticleId>
            <ArticleId IdType="pmc">PMC5811675</ArticleId>
            <ArticleId IdType="pubmed">27345726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su S, Hu B, Shao J, Shen B, Du J, Du Y, Zhou J, Yu L, Zhang L, Chen F, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070. doi:10.1038/srep20070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep20070</ArticleId>
            <ArticleId IdType="pmc">PMC4730182</ArticleId>
            <ArticleId IdType="pubmed">26818188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Zheng Y, Tang J, Wang D, Ma Z, Li S, Chang X. Stimulation of DC-CIK with PADI4 protein can significantly elevate the therapeutic efficiency in esophageal cancer. J Immunol Res. 2019;2019:6587570. doi:10.1155/2019/6587570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/6587570</ArticleId>
            <ArticleId IdType="pmc">PMC6421725</ArticleId>
            <ArticleId IdType="pubmed">30944835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724–30. doi:10.1038/s41591-018-0040-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0040-8</ArticleId>
            <ArticleId IdType="pmc">PMC6348479</ArticleId>
            <ArticleId IdType="pubmed">29867227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008;222:287–98. doi:10.1111/j.1600-065X.2008.00618.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2008.00618.x</ArticleId>
            <ArticleId IdType="pubmed">18364009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjerregaard AM, Nielsen M, Jurtz V, Barra CM, Hadrup SR, Szallasi Z, Eklund AC. An analysis of natural T cell responses to predicted tumor neoepitopes. Front Immunol. 2017;8:1566. doi:10.3389/fimmu.2017.01566.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01566</ArticleId>
            <ArticleId IdType="pmc">PMC5694748</ArticleId>
            <ArticleId IdType="pubmed">29187854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Liu S, Qu R, Li B. Recurrent neoantigens in colorectal cancer as potential immunotherapy targets. Biomed Res Int. 2020;2020:2861240. doi:10.1155/2020/2861240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/2861240</ArticleId>
            <ArticleId IdType="pmc">PMC7383341</ArticleId>
            <ArticleId IdType="pubmed">32733937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Bulk J, Verdegaal EME, Ruano D, Ijsselsteijn ME, Visser M, van der Breggen R, Duhen T, van der Ploeg M, de Vries NL, Oosting J, et al. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Med. 2019;11:87. doi:10.1186/s13073-019-0697-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-019-0697-8</ArticleId>
            <ArticleId IdType="pmc">PMC6938004</ArticleId>
            <ArticleId IdType="pubmed">31888734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 2019;9:1022–35. doi:10.1158/2159-8290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290</ArticleId>
            <ArticleId IdType="pmc">PMC7138461</ArticleId>
            <ArticleId IdType="pubmed">31164343</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
